22:53 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Mouse studies suggest inhibiting LGALS1 could help treat pancreatic ductal adenocarcinoma (PDAC). In a human KRAS (K-Ras)-expressing mouse model of PDAC, systemic LGALS1 knockout increased survival compared with normal expression. In a...
07:00 , May 16, 2016 |  BC Week In Review  |  Clinical News

Galactoarabino-rhamnogalacturonate: Completed Phase II enrollment

Galectin completed enrollment of 30 patients in the double-blind, placebo-controlled, U.S. Phase II NASH- FX trial evaluating 8 mg/kg GR-MD-02 every 2 weeks for 16 weeks. Galectin Therapeutics Inc. (NASDAQ:GALT), Norcross, Ga.   Product: Galactoarabino-rhamnogalacturonate (...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Clinical News

Galactoarabino-rhamnogalacturonate: Phase IIa started

Galectin began an open-label, U.S. Phase IIa trial to evaluate 8 mg/kg IV GR-MD-02 every 2 weeks for 7 infusions in 10 patients with >=10% of their skin affected and a PASI score of >=12...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

Galactoarabino-rhamnogalacturonate: Phase II started

Galectin began the double-blind, placebo-controlled, U.S. Phase II NASH- FX trial to evaluate 8 mg/kg GR-MD-02 every 2 weeks for 16 weeks in 30 patients. Galectin Therapeutics Inc. (NASDAQ:GALT), Norcross, Ga.   Product: Galactoarabino-rhamnogalacturonate ( GR-MD-02)...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Clinical News

Galactoarabino-rhamnogalacturonate: Additional Phase I data

Data from 9 NASH patients with advanced liver fibrosis in the third cohort of the double-blind, placebo-controlled, dose-escalation, U.S. Phase I GT-020 trial showed that infusions of 8 mg/kg IV GR-MD-02 on days 0, 21,...
07:00 , Sep 4, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Galectin-1 (LGALS1) Rodent studies suggest inhibiting LGALS1 could help treat brain tumors. LGALS1 expression in...
07:00 , Aug 4, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 8/1 cls AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) Piper Jaffray David Amsellem...
07:00 , Aug 4, 2014 |  BC Week In Review  |  Clinical News

Galactoarabino-rhamnogalacturonate: Additional Phase I data

Data from 9 NASH patients with advanced liver fibrosis in the second cohort of the double-blind, placebo-controlled, dose-escalation, U.S. Phase I GT-020 trial showed that infusions of 4 mg/kg IV GR-MD-02 on days 0, 21,...
07:00 , Aug 4, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) fell $4.44 (41%) to $6.39 on Monday after receiving a complete response letter from FDA for an NDA for Zalviso sufentanil sublingual tablet system to treat moderate-to-severe acute pain. AcelRx said...
01:12 , Jul 30, 2014 |  BC Extra  |  Clinical News

Galectin falls on NASH data for GR-MD-02

Galectin Therapeutics Inc. (NASDAQ:GALT) fell $8.84 (61%) to $5.50 on Tuesday after reporting data from the Phase I GT-020 trial of the company's GR-MD-02 to treat non-alcoholic steatohepatitis (NASH) with advanced hepatic fibrosis. In nine...